EPO revokes patent for $5bn cancer drug

12-05-2015

EPO revokes patent for $5bn cancer drug

Photo: Courtesy of EPO

The European Patent Office has revoked a patent covering biotechnology company Celgene’s cancer drug Revlimid (lenalidomide).


EPO, Celgene, Revlimid, patent revocation

LSIPR